Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Benjamin L, MD
16 Juni 2021 19:46:10
Stavudine na ujauzito
Stavudine ni dawa jamii ya NRTI inayotumika kutibu maambukizi ya VVU. Dawa hii huzuia kimeng’enya cha Revers transcriptase na Uzalishaji wa DNA ya kirusi. Dawa zingine zinazofanya kazi sawa na dawa hii ni abacavir, didanosine, lamivudine, zalcitabine na zidovudine.
Taarifa za wanyama na binadamu zinaonyesha kuwa stavudine inahatari kidogo ya madhara kwa kijusi na kichanga tumboni, kinadharia, matumizi ya stavudine kipindi cha upandikishaji wa yai lililotungishwa huweza kuzuia ujauzito kuendelea kutokana na kuwa sumu, hata hivyo hili halijafanyiwa tafiti kwa binadamu. Dozi iliyotumika kuzuia ukuaji wa kijisu kwa panya ni sawa na ile inayotumika kwa binadamu. Tafiti zingine zinaonyesha kuhusiana na madhaifu ya kazi za maitokondria ambapo tafiti zaidi zinahitajika kufanyika kuhakiki hili. Endapo itapendekezwa kutumika, isisimamishwe kwa sababu ya ujauzito.
Hakuna taarifa kuhusu madhara kwa vichanga wa mama wanaotumia dawa hii wakati wa kunyonyesha kwa sababu dawa hii hutumika kwenye matibabu ya VVU na wamama wanaotumia dawa hii huzuia unyonyesha, hata hivyo dawa hii kutokana na kuwa na uzito kidogo, hupita na kuingia kwenye maziwa ya mama.
Ushauri dhidi ya matumizi kwa mama mjamzito
Inapatana na ujauzito- faida kwa mama >>hatari kwa Kijusi-kichanga tumboni
Inapatana na ujauzito- faida kwa mama >>hatari kwa Kijusi-kichanga tumboni ina maanisha nini?
Kunaweza kuwa au kutokuwa na uzoefu wa matumizi ya dawa hii kwa binadamu, lakini faida ni kubwa zaidi zikitumiwa na mama kuliko madhara yanayofahamika au kutofahamika kuwa yanaweza kutokea kwa kijusi-kichanganya tumboni. Kwa mama dawa zinazidi madhara yanayofahammika. Taarifa za uzazi kwa wanyama hazina mahusiano
Ushauri wa matumizi kwa mama anayenyonyesha
Haipatani na unyoyenyeshaji
Haipatani na unyoyenyeshaji ina maanisha nini?
Kunawezekana kuwa hakuna taarifa za uzoefu wa matumizi ya dawa hii kwa mama anayenyonyesha. Hata hivyo mkusanyiko wa taarifa zinaonyesha kuwa dawa huweza kuwa sumu kali kwa kichanga, au haishauriwi kunyonyesha endapo dawa itahitajika kutumika kwa mama mwenye anayehitajika kutumia dawa hii. Mama anatakiwa asinyonyeshe anapotumia dawa hii au akiwa na ugonjwa unaotakiwa kutumia dawa hii.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
1 Julai 2023 17:20:53
Rejea za mada hii;
1. Product Information. Zerit. Bristol-Myers Squibb, 2001.
2. Toltzis P, Mourton T, Magnuson T. Comparative embryonic cytotoxicity of antiretroviral nucleosides. J Infect Dis 1994;169:1100–2.
3. Bawdon RE, Kaul S, Sobhi S. The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. Gynecol Obstet Invest 1994;38:1–4.
4. Odinecs A, Nosbisch C, Keller RD, Baughman WL, Unadkat JD. In vivo maternal-fetal pharmacokinetics of stavudine (2’,3’-didehydro-3’-deoxythymidine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother 1996;40:196–202.
5. Odinecs A, Nosbisch C, Unadkat JD. Zidovudine does not affect transplacental transfer or systemic clearance of stavudine (2’,3’-didehydro-3’-doxythymidine) in the pigtailed macaque (Macaca nemestrina). Antimicrob Agents Chemother 1996;40:1569–71.
6. Tuntland T, Odinecs A, Pereira CM, Nosbisch C, Unadkat JD. In vitro models to predict the in vivo mechanism, rate, and extent of placental transfer of dideoxynucleoside drugs against human immunodeficiency virus. Am J Obstet Gynecol 1999;180:198–206.
7. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2009. Wilmington, NC: Registry Coordinating Center; 2009. Available at www.apregistry.com. Imechukuliwa 16.06.2021
8. Richardson MP, Osrin D, Donaghy S, Brown NA, Hay, Sharland M. Spinal malformations in the fetuses of HIV infected women receiving combination antiretroviral therapy and co-trimoxazole. Eur J Obstet Gynecol Reprod Biol 2000;93:215–7.
9. Ristola M, Salo E, Ammala P, Suni J. Combined stavudine and lamivudine during pregnancy. AIDS 1999;13:285.
10. Gerberding JL. Management of occupational exposures to blood-borne viruses. N Engl J Med 1995;332:444–51.
11. Carpenter CCJ, Fischi MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1996. JAMA 1996;276;146–54.
12. Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol 1997;176:478–89.
13. Minkoff H. Human immunodeficiency virus infection in pregnancy. Obstet Gynecol 2003;101:797–810.
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. December 1, 2009;1–161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Imechukuliwa 16.06.2021
15. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. May 24, 2010:1–
117. Available at http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Imechukuliwa 16.06.2021Table 5.
16. Brown ZA, Watts DH. Antiviral therapy in pregnancy. Clin Obstet Gynecol 1990;33:276–89.
17. De Martino M, Tovo P-A, Tozzi AE, Pezzotti P, Galli L, Livadiotti S, Caselli D, Massironi E, Ruga E, Fioredda F, Plebani A, Gabiano C, Zuccotti GV. HIV-1 transmission through breast-milk: appraisal of risk according to duration of feeding. AIDS 1992;6:991–7.
18. Van de Perre P. Postnatal transmission of human immunodeficiency virus type 1: the breast-feeding dilemma. Am J Obstet Gynecol 1995;173:483–7.